Skip to main content

Adiponectin levels and its relation with insulin secretion and insulin sensitivity in a group of sub-Saharan African women with polycystic ovary syndrome



Low levels of adiponectin have been reported in Polycystic Ovary Syndrome (PCOS). In sub-Saharan Africa, little data are available on the topic. We aimed to investigate the levels of adiponectin and its relation with insulin secretion and insulin sensitivity in women with PCOS in Yaoundé, Cameroon. A comparative cross-sectional study was conducted in 32 women presenting PCOS and 32 controls matched for age and Body Mass Index. For each participant, adiponectin levels were measured. We estimated insulin sensitivity using Homeostasis model index (HOMA-IR) and insulin secretion with C-peptide levels.


Women with PCOS had higher insulin secretion levels than controls (C-peptide: 4.98 ± 3.83 vs 3.25 ± 1.62 mUI/l; p = 0.02). Also, the HOMA-IR index was higher compared to that of women without PCOS (1.15 ± 0.90 vs 0.77 ± 0.38; p = 0.03) suggesting greater insulin resistance. The median [25th–75th percentile] values of adiponectin concentrations were similar between the two groups (22.68 [21.72–23.41] μg/ml vs 22.03 [21.40–22.93] μg/ml; p = 0.1). There was no association between insulin sensitivity and adiponectin levels in the PCOS group. PCOS is not associated with changes in adiponectin in a population of sub-Saharan African women. Further studies are needed to shed more light on this condition.


Polycystic ovary syndrome (PCOS) is a complex and heterogenous condition characterized by hyperandrogenism, ovulatory dysfunction and polycystic ovarian morphology (PCOM) [1, 2]. It affects women of reproductive age worldwide with an estimated prevalence of 5–20% [1]. Metabolic abnormalities, mainly insulin resistance (IR) and compensatory hyperinsulinemia, are evident in a majority of affected individuals, especially among those women who also show hyperandrogenism [1]. It has been shown that 50–70% of women with PCOS are insulin resistant [3], half of them are overweight or obese with 5–7-folds increased risk of Type 2 diabetes (T2D) [4]. The mechanisms of IR in this condition remain poorly elucidated. Initially, IR was considered a consequence of obesity and overweight usually found in PCOS. However, recent evidence suggests that insulin resistance in PCOS might be independent of obesity [5]. In search of mechanisms and associated factors of IR, adipokines were proposed as a potential actor in the development of IR in PCOS [6]. Adiponectin is one of the most abundant adipokine, plays an important role in energy metabolism and contributes to the pathogenesis of the metabolic syndrome [6, 7]. It also exhibits anti-inflammatory, anti-atherogenic and insulin-sensitizing effects [8]. Reduced levels of adiponectin have been associated with insulin resistance indicating a potential role in the development of metabolic disorders [9]. Given that, it has been suggested that adiponectin levels might be altered in PCOS participating to IR in this condition. However, this relationship between adiponectin levels and IR in PCOS remains debatable. Studies reports opposing results with some studies finding lower adiponectin levels in PCOS independent of BMI [10,11,12], and others reporting similar adiponectin levels in BMI-matched PCOS and controls [13, 14]. But while these data are accumulating in different populations, data on this issue are lacking on sub-Saharan African populations. Therefore, studies are needed to provide data on this topic on a population where metabolic disorders are highly prevalent [15]. In this light, we aimed to study the levels of adiponectin in cameroonian women living with PCOS.

Main text

Materials and methods


This comparative cross-sectional study was conducted from March to June 2020 at the Yaoundé Gynaeco-Obstetric and Paediatric Hospital and at the laboratory of the Yaoundé Central Hospital. We included women of reproductive age (15–44 years) living with PCOS and controls matched for age and BMI (ratio 1:1). PCOS was defined according to the 2003 Rotterdam diagnosis criteria of PCOS; we therefore included in the PCOS group, women with at least 2 of the following criteria: (1) oligo-or anovulation; (2) clinical and/or biological hyperandrogenism; (3) polycystic morphology of ovary in ultrasound examination (at least 12 follicles with a diameter of 2 to 9 mm and/or volume ≥ 10 ml per ovary) [16]. Control subjects were healthy women recruited in the community, with no menstrual cycle disorders and no signs of clinical hyperandrogenism. We did not include women with any of the following conditions: pregnancy or breastfeeding, known diabetes mellitus, known chronic diseases or other hyperandrogenemia conditions (late-onset congenital adrenal hyperplasia, Cushing syndrome, androgen secreting tumors, and thyroid dysfunction). In addition, oral contraceptives or drugs that could affect hormonal and metabolic profiles were discontinued at least 3 months before inclusion in the study.

Data collection

For each subject, we measured weight with an automatic scale (CAMRY®, Hong Kong, China) and Height with a stadiometer. Waist circumference (WC) and hip circumference (HC) were measured using a measuring tape. We calculated Waist-to-hip ratio (WHR) as \(\frac{\mathrm{WC}}{\mathrm{HC}}\) and body mass index (BMI) using the Quetelet’s formula as BMI = weight/height2 (kg/m2). We grouped participants into 3 categories according to BMI: normal BMI (18.5–24.9 kg/m2), overweight (25.0–29.9 kg/m2) or obese (≥ 30 kg/m2) [17]. We measured resting blood pressure using standardized procedures with a validated automated blood pressure measuring device, Omron HEM-757(Omron Corporation, Tokyo, Japan).

Blood samples and laboratory investigations

After twelve hours of overnight fast, 10 ml of venous blood were collected in the morning on the antecubital vein in dry tube and sodium fluoride tube. Fasting plasma glucose levels were determined the same day by an enzymatic colorimetric method using BIOLABO® kits (France). Serum was then aliquoted and stored at − 20 °C for further biochemical analysis (C-peptide and adiponectin). C-peptide and adiponectin were measured by an indirect sandwich Enzyme Linked Immuno-Sorbent Assay (ELISA) method (ELABSCIENCE® kits, USA).

Determination of insulin resistance

We used the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR). This was determined by the formula: Fasting blood glucose (mmol/l) × Fasting insulin (µUI/ml)/22.5) where insulin was replaced by the C-peptide level as previously published in our context [18, 19].

Statistical analysis

Data were analyzed using SPSS version 23.0 software (IBM Corporation, Chicago, Illinois, USA). For quantitative variables, results are presented as mean ± Standard Deviation (SD) for normally distributed data or median (25th–75th percentiles) when normality was not verified. For categorical variables, results are presented as counts (percentages). We used the Chi-square test to study association between categorical variables. The Student’s T-test and non-parametric test (Mann–Whitney U-test) were used for group’s comparison of quantitative variables. Spearman’s correlation test was used to assess the linear association between skewed quantitative data and logistic regression to assess independent variables associated with PCOS. The receiver operating characteristic (ROC) curve analysis was used to evaluate the performance of adiponectin and Waist-to-hip ratio (WTH) in predicting PCOS. The significance threshold was set at p < 0.05.


Characteristics of the study population

Overall, we enrolled 32 women with PCOS with a mean age of 26.7 ± 4.7 (20–38) years. Of these women, 31.3% had normal BMI, 31.3% were overweight and 37.4% were obese. The general characteristics of participants are summarized in (Table 1).

Table 1 Clinical characteristics of participants

Insulin resistance and adiponectin levels

Women with PCOS had higher C-peptide levels compared to the controls (4.98 ± 3.83 vs. 3.25 ± 1.62 mUI/l; p = 0.02), whereas their fasting plasma glucose levels were similar (5.27 ± 1.05 vs. 5.35 ± 0.94 mmol/l; p = 0.75). As a result, their HOMA-IR index was higher compared to that of women without PCOS (1.15 ± 0.90 vs. 0.76 ± 0.38; p = 0.03). Serum levels of adiponectin were similar between the two groups (Table 2).

Table 2 Biochemical characteristics of participants

In women with PCOS, we didn’t find any correlation between adiponectin levels and the HOMA-IR index (p = 0.23) on one hand, nor between adiponectin levels and C-peptide, fasting plasma glucose, or BMI on the other hand (Table 3). After logistic regression analysis, we found that Waist-to-hip ratio was independent factor associated with PCOS (Additional file 1: Table S1). Waist-to-hip ratio presented with the best power in predicting PCOS (AUC = 0.76) followed by adiponectin (AUC = 0.62) (Additional file 1: Fig. S1).

Table 3 Correlation between adiponectin levels and HOMA-IR index, C-peptide, fasting plasma glucose, Body mass index


PCOS is frequently associated with IR leading to compensatory hyperinsulinemia [1]. In the present study, women with PCOS had a high HOMA-IR index compared to matched controls suggesting greater insulin resistance. These results are consistent with those of Amer et al. in Egypt where cases were more insulin resistant than controls using the same index [10]. In addition, Doh et al. in their report in fourteen Cameroonian women with PCOS, also found a low level of insulin sensitivity using the euglycemic hyperinsulinemic clamp, the reference method for estimating insulin sensitivity [20]. The C-peptide levels obtained, reflecting insulin secretion, were significantly higher in the PCOS group than controls suggesting hyperinsulinemia in this population as expected. In women with PCOS, basal insulin secretion rates are increased, although insulin secretory responses to a glucose load are generally inadequate resulting in a lower glucose disposition index than age and BMI-matched controls [21]. Despite the presence of hyperinsulinemia, women with PCOS are thought to have pancreatic β­cell dysfunction and also demonstrate decreased hepatic clearance of insulin [22]. Insulin potentiates steroidogenic response to gonadotrophins both in vivo and in vitro; hence, during hyperinsulinemia there will be elevated androgen levels. This increase androgen activity is associated with IR [23]. It has been hypothesized that PCOS results from a vicious circle of androgen excess favoring abdominal adipose tissue deposition and visceral adiposity by inducing IR and compensatory hyperinsulinism, which further facilitates androgen secretion by the ovaries and adrenal glands in women with PCOS [24].

Adiponectin values obtained in PCOS women fall within the known normal range of 5-30 µg/mL and were similar to the controls group [9]. Some studies report similar results in BMI-matched PCOS and controls [13, 14] whiles other report low levels of adiponectin independent of BMI [10,11,12]. As in our study, the authors did not find a relation between adiponectin levels and insulin resistance [11]. They attributed this changes to fat distribution and variable amount of subcutaneous and high visceral fat [11, 25]. In our study, we found that WTH was independent factor associated with PCOS and have the best discriminatory power in predicting PCOS with an AUC of 0.76. One study showed that it can be used as indirect predictors of visceral obesity in women with PCOS [26]. Therefore, this abdominal obesity could cause additional disturbances in metabolic and hormonal parameters in PCOS [27]. The comparable results between PCOS and controls in our study suggest a relatively increase level of adiponectin in our population. Considering that this is the first study in this population, we speculate that this relative increase in adiponectin may reflect a resistance to its action [28]. This can either be a low sensitivity to this hormone, or a post-receptor resistance leading to a compensatory mechanism increasing hormonal levels.

We did not found a relation between adiponectin levels and insulin sensitivity in women with PCOS. Similar results were reported in Poland population [29]. However, studies in the Caucasian population report an association between adiponectin and insulin sensitivity [12, 30]. These discrepancies between our findings and reports in other populations further stress the need of studies on the question in sub-Saharan populations.


Sub-Saharan African women with PCOS do not present lower adiponectin levels despite higher insulin resistance and high insulin secretion levels. Further studies are needed to shed more light on this condition.


Firstly, we used C-peptide measurement to access insulin level base on their equimolar secretion in blood. Therefore, it can be indirectly measured to access insulin secretion [31]. Secondly, HOMA-IR index was used to determine insulin sensitivity instead of the gold standard method (the euglycaemic hyperinsulinic clamp) used in a small number of subjects [32]. Although, studies recommend the use of HOMA-IR index when it is impossible or difficult to perform [33]. In addition, the HOMA-IR index is more suitable for population and epidemiological studies [18].

Availability of data and materials

Data will be available from the corresponding author upon request.



Body mass index


Hip circumference


Homeostasis Model Assessment of Insulin Resistance


Polycystic ovary syndrome


Insulin resistance


Standard deviation


Type 2 diabetes


Waist circumference


Waist to Hip Ratio


Area under the curve


Receiver operating characteristic


  1. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JSE, Legro RS, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2(1):16057.

    Article  PubMed  Google Scholar 

  2. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 2010;8(1):41.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009;91(2):456–88.

    Article  PubMed  Google Scholar 

  4. Azziz R, Adashi EY. Stein and Leventhal: 80 years on. Am J Obstet Gynecol. 2016;214(2):247.e1-247.e11.

    Article  Google Scholar 

  5. Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod. 2013;28(3):777–84.

    CAS  Article  PubMed  Google Scholar 

  6. Eckel J. Adipose tissue. In: Eckel J, editor. The cellular secretome and organ crosstalk. Cambridge: Academic press; 2018. p. 9–63.

    Chapter  Google Scholar 

  7. Polak K, Czyzyk A, Simoncini T, Meczekalski B. New markers of insulin resistance in polycystic ovary syndrome. J Endocrinol Invest. 2017;40(1):1–8.

    CAS  Article  PubMed  Google Scholar 

  8. Stern JH, Rutkowski JM, Scherer PE. Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell Metab. 2016;23(5):770–84.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: lessons from translational research. Am J Clin Nutr. 2010;91(1):258S-261S.

    CAS  Article  PubMed  Google Scholar 

  10. Amer H, Abo-Shady R, Elaziz D, Khattab Y. The role of serum adiponectin levels in women with polycystic ovarian syndrome. Egypt J Hosp Med. 2017;68:837–44.

    Article  Google Scholar 

  11. Carmina E, Orio F, Palomba S, Cascella T, Longo RA, Colao AM, et al. Evidence for altered adipocyte function in polycystic ovary syndrome. Eur J Endocrinol. 2005;152(3):389–94.

    CAS  Article  PubMed  Google Scholar 

  12. Ardawi MSM, Rouzi AA. Plasma adiponectin and insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2005;83(6):1708–16.

    CAS  Article  PubMed  Google Scholar 

  13. Orio F, Palomba S, Cascella T, Milan G, Mioni R, Pagano C, et al. Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88(6):2619–23.

    CAS  Article  PubMed  Google Scholar 

  14. Lecke SB, Mattei F, Morsch DM, Spritzer PM. Abdominal subcutaneous fat gene expression and circulating levels of leptin and adiponectin in polycystic ovary syndrome. Fertil Steril. 2011;95(6):2044–9.

    CAS  Article  PubMed  Google Scholar 

  15. Maya ET, Guure CB, Adanu RMK, Sarfo B, Ntumy M, Bonney EY, et al. Why we need epidemiologic studies of polycystic ovary syndrome in Africa. Int J Gynecol Obstet. 2018;143(2):251–4.

    Article  Google Scholar 

  16. Tr E, ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19–25.

    Article  Google Scholar 

  17. World Health Organization. Obesity: preventing and managing the global epidemic Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894(i–xii):1–253.

    Google Scholar 

  18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.

    CAS  Article  PubMed  Google Scholar 

  19. Noumegni SR, Bigna JJ, Ama Moor epse Nkegoum VJ, Nansseu JR, Assah FK, Jingi AM, et al. Relationship between estimated cardiovascular disease risk and insulin resistance in a black African population living with HIV: a cross-sectional study from Cameroon. BMJ Open. 2017;7(8): e016835.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Doh E, Mbanya A, Kemfang-Ngowa JD, Dohbit S, Tchana-Sinou M, Foumane P, et al. The relationship between adiposity and insulin sensitivity in african women living with the polycystic ovarian syndrome: a clamp study. Int J Endocrinol. 2016;2016:1–6.

    Article  Google Scholar 

  21. Ehrmann DA, et al. Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest. 1995;96:520–7.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  22. Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev. 1997;18(6):774–800.

    CAS  PubMed  Google Scholar 

  23. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC. The insulin-related ovarian regulatory system in health and disease. Endocr Rev. 1999;20(4):535–82.

    CAS  Article  PubMed  Google Scholar 

  24. Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270–84.

    Article  PubMed  Google Scholar 

  25. Aroda V, Ciaraldi TP, Chang S-A, Dahan MH, Chang RJ, Henry RR. Circulating and cellular adiponectin in polycystic ovary syndrome: relationship to glucose tolerance and insulin action. Fertil Steril. 2008;89(5):1200–8.

    CAS  Article  PubMed  Google Scholar 

  26. Kałużna M, Czlapka-Matyasik M, Bykowska-Derda A, Moczko J, Ruchala M, Ziemnicka K. Indirect predictors of visceral adipose tissue in women with polycystic ovary syndrome: a comparison of methods. Nutrients. 2021;13(8):2494.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Franik G, Bizoń A, Włoch S, Pluta D, Blukacz Ł, Milnerowicz H, et al. The effect of abdominal obesity in patients with polycystic ovary syndrome on metabolic parameters. Eur Rev Med Pharmacol Sci. 2017;21(21):4755–61.

    CAS  PubMed  Google Scholar 

  28. Engin A. Adiponectin-resistance in obesity. In: Engin AB, Engin A, editors. Obesity and lipotoxicity. Cham: Springer International Publishing; 2017. p. 415–41.

    Chapter  Google Scholar 

  29. Olszanecka-Glinianowicz M, Kuglin D, Dąbkowska-Huć A, Skałba P. Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol. 2011;154(1):51–6.

    CAS  Article  PubMed  Google Scholar 

  30. Liu X, Zhang J, Li Y, et al. On the relationship between serum total adiponectin and insulin resistance in polycystic ovary syndrome. Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2010;27:636–40.

    CAS  PubMed  Google Scholar 

  31. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve -cell function: report of an ADA workshop, 21–22 october 2001. Diabetes. 2004;53(1):250–64.

    CAS  Article  PubMed  Google Scholar 

  32. Wallace T, Matthews D. The assessment of insulin resistance in man. Diabet Med. 2002;19:527–34.

    CAS  Article  PubMed  Google Scholar 

  33. Bonora E, Targher G, Alberiche M, Bonadonna R, Saggiani F, Zenere M, et al. Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care. 2000.

    Article  PubMed  Google Scholar 

Download references


We gratefully acknowledge all the patients who have accepted to take part in this study.



Author information

Authors and Affiliations



ASM, ATT and SPC designed the study; ASM, JVAM, YD, JN, EAMS, FA, MGF, CCN, FDT, SG, JDS and SPC collected the data; ASM, ATT, GSW performed the statistical analysis; ASM, JVAM, ATT and SPC drafted the manuscript; All authors have read and approved the final manuscript.

Corresponding author

Correspondence to Audrey Synthia Momo.

Ethics declarations

Ethical approval and consent to participate

The study protocol was approved by the Institutional Research Ethical Committee of the Faculty of Medicine and Biomedical Sciences, Yaoundé and by the Centre Regional Ethics Committee for Human Health Research (N˚0620/CRERSHC/2020). All participants signed a written informed consent form.

Consent for publication

Not applicable.

Competing interests

None declared.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Table S1.

Logistic regression including key independent variables and factors associated with PCOS. Figure S1. Receiver operating characteristic (ROC) curve was based on binary logistic regression and classification analysis for PCOS and control group. AUC: Area under the curve.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Momo, A.S., Ama Moor, V.J., Tankeu, A.T. et al. Adiponectin levels and its relation with insulin secretion and insulin sensitivity in a group of sub-Saharan African women with polycystic ovary syndrome. BMC Res Notes 15, 24 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI:


  • Adiponectin
  • Polycystic ovary syndrome
  • Insulin sensitivity